U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06842524) titled 'Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome' on Feb. 19.
Brief Summary: Polycystic ovarian syndrome (PCOS) is the most frequent endocrine disorder affecting women of reproductive age, with a prevalence of 10 to 13%. PCOS is characterized by irregular menstrual cylcles/ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology. For infertile patients seeking ovulation induction, letrozole is the drug of first choice. For PCOS patients not seeking pregnancy, there exists a variety of treatments to alleviate symptoms. It has been demonstrated that artemisinin derivatives can promote energy expendit...